<DOC>
	<DOCNO>NCT02444429</DOCNO>
	<brief_summary>Renal transplantation represent currently best therapeutic alternative end-stage renal failure , term patient outcome ( good quality life longer survival ) , also term cost society . Progress achieve last 20 year result drastic reduction incidence `` classic '' ( i.e . clinically patent ) acute cellular rejection episode . Unfortunately , rather unexpectedly , progress hardly effect frequency loss kidney transplant beyond first year , show stagnation graft ' half life . Furthermore , use immunosuppressant combination powerful impact adverse effect recipient , include increase incidence infection , cancer , also metabolic complication ( diabetes , osteoporosis , dyslipidemia , etc . ) , cause significant morbi-mortality . In attempt improve disappointing outcome , team offer perform screen biopsy : i.e . routine biopsy specific time point follow , irrespective graft function . Their primary interest allow pathological analysis graft early stage , i.e . potential histological lesion allow diagnosis lesion impact graft 's function . Indeed , clearly demonstrate therapeutic adjustment intend protect graft effective introduce early . There fairly broad consensus perform biopsy three month one year transplantation . Performing screen biopsy lead identification `` subclinical '' form rejection , i.e . graft infiltration recipient immune effector meet Banff histological criterion , without increase creatininemia . Assuming 10 % screen biopsy perform 3 month reveal subclinical rejection , need treat , management strategy remain 90 % patient , whose biopsy show either ) mild inflammatory infiltrates : i.e . `` borderline change '' , ii ) complete absence immune effector graft , poorly standardize . The investigator therefore propose conduct prospective randomize trial answer question simultaneously evaluate strategy optimize immunosuppression renal graft recipient base presence absence subclinical intragraft inflammatory infiltrate screen biopsy perform 3 month post transplantation . Patients borderline change ( sub-study A ) randomize receive treatment rejection ( corticosteroid bolus ) . Patients without inflammation graft ( sub-study B ) randomize corticosteroid withdrawal . Impact graft function , progression histological lesion incidence morbidity evaluate .</brief_summary>
	<brief_title>3-month Screening Biopsy Optimize Immunosuppression Renal Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Common substudies ( A B ) Renal transplant patient age 18 70 . Patient receive first second renal graft Immunosuppressive treatment consist anticalcineurin [ cyclosporine ( trough level : 150 &lt; T0 &lt; 300 ) ] , tacrolimus ( trough level : 8 &lt; T0 &lt; 12 ) , mycophenolate mofetil , corticosteroid , monoclonal ( Simulect ) polyclonal ( ATG ) antibody induction . Patient benefit screen renal biopsy 3 month graft Patient give inform consent Patient affiliate social security scheme beneficiary scheme 2 . Specific substudy A Presence `` borderline '' inflammatory infiltrate screen biopsy 3 month define Banff classification 2013 : absence vascular lesion ( v0 ) : tubulitis regardless significance ( t13 ) minimum interstitial infiltrate ( i0i1 ) OR interstitial infiltrates ( i23 ) without significant tubulitis ( â‰¤ t1 ) 3 . Specific substudy B Absence significant inflammatory infiltrates ( i01 t0 ) screen biopsy 3 month 1 . Common substudies ( A B ) Histological subclinical rejection criterion screen biopsy 3 month ( Banff 2009 : &gt; i2+t2 ) Donor specific antibody historical serum de novo appearance first 3 month Humoral lesion 3month biopsy ( Banff score g+ptc &gt; 2 C4d &gt; 0 ) `` Classic '' acute rejection episode proven biopsy first 3 month Multiorgan transplantation 3rd ( subsequent ) renal transplantation BK virusassociated nephropathy screen biopsy Contraindication 1year screen biopsy 2 . Specific substudy B Initial nephropathy high risk recurrence corticosteroid withdrawal : segmental focal segmental glomerulosclerosis , lupus nephritis , vasculitis , membranous glomerulonephritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Screening renal biopsy</keyword>
	<keyword>Immunosuppression</keyword>
</DOC>